| Host: |
HEK293 |
| Note: |
STRICTLY FOR FURTHER RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Recombinant-Human TGF Beta-1 receptor 2 (TGRBR2)-protein was developed from hek293. For use in research applications. |
| Conjugation: |
Unconjugated |
| Formulation: |
Lyophilised from 0.2 Mu m filtered 100mM Glycine, 10mM NaCl, 50mM Tris, pH 7.5. |
| Dilution Range: |
Spin the vial and reconstite in distilled water to a concentration not less than 0.1 mg/mL. This can then be diluted into other buffers. |
| Storage Instruction: |
Can be stored in working aliquots at 2°C-8°C C for one month, or at-20°C C for six months. Avoid repeated freeze/thaw cycles. NA |
| Endotoxin: |
Endotoxin content was assayed using a LAL gel clot method. Endotoxin level was found to be less than 0.1 ng/µg (1EU/µg). NA |
| Immunoreactivity: |
The ED (50) was determined by the ability to bind TGFb1 and was found to be 1-3 ug/ml in the presence of TGFb1 at a concentration of 1ng/ml. NA |
| Gene Symbol: |
TGFBR2 |
| Gene ID: |
7048 |
| Uniprot ID: |
TGFR2_HUMAN |
| Immunogen Region: |
ECD |
| Immunogen: |
Optimized DNA sequence encoding Human TGF beta receptor 2 extracellular domain fused to an Fc domain was expressed in HEK293 cells NA |
| Function | Transmembrane serine/threonine kinase forming with the TGF-beta type I serine/threonine kinase receptor, TGFBR1, the non-promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3. Transduces the TGFB1, TGFB2 and TGFB3 signal from the cell surface to the cytoplasm and thus regulates a plethora of physiological and pathological processes including cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. The formation of the receptor complex composed of 2 TGFBR1 and 2 TGFBR2 molecules symmetrically bound to the cytokine dimer results in the phosphorylation and activation of TGFBR1 by the constitutively active TGFBR2. Activated TGFBR1 phosphorylates SMAD2 which dissociates from the receptor and interacts with SMAD4. The SMAD2-SMAD4 complex is subsequently translocated to the nucleus where it modulates the transcription of the TGF-beta-regulated genes. This constitutes the canonical SMAD-dependent TGF-beta signaling cascade. Also involved in non-canonical, SMAD-independent TGF-beta signaling pathways. Isoform 1: Has transforming growth factor beta-activated receptor activity. Isoform 2: Has transforming growth factor beta-activated receptor activity. Isoform 3: Binds TGFB1, TGFB2 and TGFB3 in the picomolar affinity range without the participation of additional receptors. Blocks activation of SMAD2 and SMAD3 by TGFB1. |
| Protein Name | Tgf-Beta Receptor Type-2Tgfr-2Tgf-Beta Type Ii ReceptorTransforming Growth Factor-Beta Receptor Type IiTgf-Beta Receptor Type IiTbetar-Ii |
| Database Links | Reactome: R-HSA-2173788Reactome: R-HSA-2173789Reactome: R-HSA-2173791Reactome: R-HSA-3304356Reactome: R-HSA-3642279Reactome: R-HSA-3645790Reactome: R-HSA-3656532Reactome: R-HSA-3656535Reactome: R-HSA-5689603 |
| Cellular Localisation | Cell MembraneSingle-Pass Type I Membrane ProteinMembrane RaftIsoform 3: Secreted |
| Alternative Protein Names | Tgf-Beta Receptor Type-2 proteinTgfr-2 proteinTgf-Beta Type Ii Receptor proteinTransforming Growth Factor-Beta Receptor Type Ii proteinTgf-Beta Receptor Type Ii proteinTbetar-Ii proteinTGFBR2 protein |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
